SCHEMBL5834869

SCHEMBL5834869

CCCNc1ccc(N)cc1-c1nc2cc(-c3cc4ccccc4s3)ccc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 10/20 0.46
APP P05067 1/20 0.42
MAPT P10636 8/20 0.42
SMN1; SMN2 Q16637 7/20 0.42
NPC1 O15118 7/20 0.42
RAB9A P51151 7/20 0.42
TP53 P04637 6/20 0.42
KDM4E B2RXH2 5/20 0.42
HSD17B10 Q99714 4/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 5/20 0.41
ALDH1A1 P00352 5/20 0.41
KMT2A Q03164 5/20 0.41
HPGD P15428 4/20 0.41
ALOX15 P16050 2/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835166 0.85 HPSE (0.45) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834258 0.85 HPSE (0.59) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834742 0.82 HPSE (0.47) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5835102 0.81 MAPT (0.47) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834861 0.81 HPSE (0.47) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834501 0.80 APP (0.46) APPMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834746 0.80 MAPT (0.46) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834161 0.80 HPSE (0.59) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834442 0.80 HPSE (0.59) HPSEMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL5834486 0.79 HPSE (0.61) HPSEMAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138425-B2 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2006-11-21 US disclosed
US-20050203153-A1 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2005-09-15 US disclosed
EP-1483261-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) 2004-12-08 EP disclosed
WO-2003074516-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203153-A1 Phthalimide carboxylic acid derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 HPSE 2626/4885APP 2959/4885MAPT 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.